Predictive biomarkers to anti-VEGF therapy: progress towards an elusive goal

摘要

The search for reliable biomarkers predictive of response to anti-VEGF therapy has been elusive. VEGF-A, the therapeutic target of bevacizumab, is an intuitive candidate as a predictive biomarker to bevacizumab-based anticancer therapy. However, there remains much controversy in the utility of VEGF-A as a predictor of response to bevacizumab.